ArQule(NASDAQ:ARQL) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 3, 2016. Company reported revenue of $1.07M. Analysts estimated a revenue of $1.13M. Earnings per share were $-0.07. Analysts had estimated an EPS of $-0.08.
ArQule (ARQL) shares turned negative on Fridays trading session with the shares closing down -0.08 points or -5.10% at a volume of 1,99,848. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.61. The peak price level was also seen at $1.61 while the days lowest was $1.49. Finally the shares closed at $1.49. The 52-week high of the shares is $2.65 while the 52-week low is $1.37. According to the latest information available, the market cap of the company is $106 M.
Several Insider Transactions has been reported to the SEC. On Dec 18, 2015, Michael D Loberg (director) purchased 3,719 shares at $2.16 per share price.Also, On Dec 16, 2015, Paolo Pucci (CEO) purchased 1,283 shares at $2.16 per share price.On Dec 14, 2015, Patrick J Zenner (director) purchased 2,300 shares at $2.15 per share price, according to the Form-4 filing with the securities and exchange commission.
ArQule Inc. is a clinical-stage biotechnology company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs target biological pathways implicated in a range of cancers and certain non-oncology indications. Its product candidates and programs are based on biological processes that lead to the proliferation and metastasis of cancer cells combined with generating product candidates possessing certain pre-selected drug-like properties. Its lead product candidate is tivantinib (ARQ 197) an orally administered small molecule inhibitor of the c-Met receptor tyrosine kinase (c-MET or MET) and its biological pathway. The Company’s product candidates include ARQ 092 ARQ 087 ARQ 751 and ARQ 761.